Craft

Advanced
GSKGSK
GSK

GSK

GSK Summary

Overview

GSK (GlaxoSmithKline) is a science-led healthcare company. It has three businesses that research, develop, and manufacture pharmaceutical medicines, vaccines, and consumer healthcare products. The company develops vaccines against infectious diseases and provides a portfolio of medicines in respiratory, HIV, immuno-inflammation, and oncology. GSK combines science and consumer insights aiming to create everyday healthcare brands for oral health, pain relief, cold, flu and allergy relief, digestive health, and vitamins, minerals, and supplements.

TypePublic
Founded2000
HQBrentford, GBMap
Websitegsk.com
Employee Ratings
4		More
  • homepage icon
  • linkedin icon
  • instagram icon
  • facebook icon
  • youtube icon
  • twitter icon
View Jobs (2)

Locations

GSK is headquartered in
Brentford, United Kingdom

Location Map
All Locations (91)

Latest Updates

Company Growth (employees)

Employees (est.) (Dec 2019)99,437(+4%)
Job Openings2
Website Visits (Nov 2020)2 m(-7%)
Revenue (FY, 2019)£33.8 B(+10%)
Share Price (Jan 2021)£14.1(+1%)
Cybersecurity ratingBMore

Table of Contents

Key People/Management at GSK

Show more

GSK Office Locations

GSK has offices in Brentford, Philadelphia, Tirane, Boudouaou and in 87 other locations

Show all (91)

GSK Financials and Metrics

GSK Revenue

View revenue for all periods

GSK's revenue was reported to be £33.75 b in FY, 2019 which is a 9.5% increase from the previous period.

GBP

Revenue (Q3, 2020)£8.65 b
Gross profit (Q3, 2020)£5.76 b
Gross profit margin (Q3, 2020), %66.6%
Net income (Q3, 2020)£1.43 b
EBIT (Q3, 2020) £1.86 b
Market capitalization (15-Jan-2021)£71.1 b
Closing stock price(15-Jan-2021)£14.14
Cash (30-Sept-2020)£4.28 b
EV $95.07 b

GSK's current market capitalization is £71.1 b.

GBPFY, 2016FY, 2017FY, 2018FY, 2019
Revenue27.9 b30.2 b30.8 b33.8 b
Revenue growth, %17%8%2%10%
Cost of goods sold9.3 b10.3 b10.2 b11.9 b
Gross profit18.6 b19.8 b20.6 b21.9 b
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Revenue7.4 b7.3 b7.8 b7.2 b7.3 b8.1 b7.7 b7.8 b9.4 b9.1 b7.6 b8.6 b
Cost of goods sold2.5 b2.6 b2.7 b2.4 b2.3 b2.6 b2.7 b2.6 b3.2 b3.2 b2.4 b2.9 b
Gross profit4.9 b4.7 b5.2 b4.8 b5 b5.5 b4.9 b5.2 b6.1 b5.9 b5.2 b5.8 b
Gross profit Margin, %66%64%66%67%68%67%64%66%66%65%68%67%
show all

GBPFY, 2016FY, 2017FY, 2018FY, 2019
Cash4.9 b3.8 b3.9 b4.7 b
Accounts Receivable4.6 b4.7 b5.2 b5.5 b
Inventories5.1 b5.6 b5.5 b5.9 b
Current Assets16.7 b15.9 b16.9 b19.5 b
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Cash4.5 b4 b4.7 b4 b4 b3.8 b4.1 b4.1 b4.3 b4.8 b8.2 b4.3 b
Inventories5.4 b5.7 b5.7 b5.7 b5.9 b5.8 b5.7 b6 b6.8 b6 b6.4 b6.4 b
Current Assets16.8 b16.4 b17.7 b16.4 b17 b17.4 b17.5 b18.2 b21 b22 b23 b19.9 b
PP&E10.8 b10.7 b10.6 b10.7 b10.8 b10.9 b10.3 b10.4 b10.7 b10.4 b10.5 b10.3 b
show all

GBPFY, 2016FY, 2017FY, 2018FY, 2019
Net Income1.1 b2.2 b4 b5.3 b
Depreciation and Amortization1.6 b1.9 b1.9 b2.3 b
Accounts Receivable(188 m)(287 m)(984 m)(32 m)
Inventories70 m(461 m)51 m300 m
GBPQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020
Depreciation and Amortization326 m1.4 b2.1 b478 m673 m1.2 b1.2 b2 b2.5 b194 m(971 m)(330 m)
Cash From Operating Activities1.1 b2.2 b4 b863 m2.2 b4.3 b663 m2.1 b5.6 b965 m3.7 b4.6 b
Purchases of PP&E(260 m)(639 m)(1 b)(258 m)(541 m)(842 m)(222 m)(501 m)(785 m)(197 m)(420 m)(712 m)
Cash From Investing Activities(199 m)(646 m)(1.1 b)(371 m)(633 m)(1.1 b)(4 b)(4.5 b)(5 b)(58 m)2.8 b2.2 b
show all

GBP
Q3, 2020
EV/EBIT52.1 x
EV/CFO21.1 x
Debt/Equity1.4 x
Debt/Assets0.3 x
Financial Leverage3.9 x
P/E Ratio58.8 x

  • GSK Market Cap History

  • GSK Stock Price

Show all financial metrics

Revenue Breakdown

GSK revenue breakdown by business segment: 26.7% from Consumer Healthcare, 21.2% from Vaccines and 52.1% from Global Pharmaceuticals

GSK revenue breakdown by geographic segment: 23.9% from Europe, 34.9% from International and 41.2% from US

GSK Operating Metrics

GSK's Consumer Healthcare Products Produced was reported to be 4.2 b in FY, 2019.

FY, 2016FY, 2017FY, 2018FY, 2019
Consumer Healthcare Products Produced5 b6.2 b3.8 b4.2 b
Volume of Medicines Produced2 b1.9 b2.3 b2.3 b
Vaccines833 m798 m770 m701 m
Vaccine Doses Delivered per Day2 m2 m2 m2 m
Show all operating metrics

GSK Acquisitions / Subsidiaries

Company NameDateDeal Size
Sitari PharmaceuticalsSeptember 12, 2019
TESARODecember 04, 2018$5.1 b
NovartisMarch 27, 2018$13 b
GlycoVaxynFebruary 11, 2015$190 m
Okairos AGMay 29, 2013$325 m
Human Genome SciencesAugust 03, 2012$3 b
CellZomeMay 15, 2012£61 m
MaxiNutritionDecember 13, 2010£162 m
Nanjing MeiRui Pharma Co., Ltd.December 07, 2010$70 m
Laboratorios PhoenixJune 09, 2010$253 m

Human Capital Metrics

Source: Company Filings FY 2016, Company Filings FY 2016, Company Filings FY 2016

GSK Hiring Categories

GSK Median Salaries

Source: 9 public H-1B filings from GSK

Show all human capital metrics

GSK Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

GSK Website Traffic

Alexa Website Rank

Total Visits per monthSimilarWeb

GSK Online and Social Media Presence

Twitter followers

215.95 k Twitter followers

6 Months

GSK has 215.95 k Twitter Followers. The number of followers has increased 0.82% month over month and increased 2.71% quarter over quarter.

GSK's Trends

Search term - GSK

Twitter Engagement Stats for @gsk

  • 12.09 k

    Tweets

  • 713

    Following

  • 215.95 k

    Followers

  • 36

    Tweets last 30 days

  • 21.2

    Avg. likes per Tweet

  • 80.6%

    Tweets with engagement

GSK Technology StackBuildWith Logo

  • ads

    7 products used

    • DoubleClick.Net
    • Facebook Custom Audiences
    • Google Remarketing
      • JW Player Tracking
      • Rocket Fuel
      • travel audience
      • Twitter Ads

  • analytics

    14 products used

    • Adobe Marketing Cloud
    • Clicktools
    • Facebook Signal
      • Global Site Tag
      • Google Analytics
      • Google Analytics Enhanced Link Attribution
      • Google Conversion Tracking
      • Google Universal Analytics
      • New Relic
      • Omniture SiteCatalyst
      • Quantcast Measurement
      • Twitter Analytics
      • Twitter Conversion Tracking
      • Twitter Website Universal Tag

  • cdn

    9 products used

    • AJAX Libraries API
    • Akamai
    • Amazon S3
      • Azure Edge
      • Content Delivery Network
      • Microsoft Azure Blob Storage
      • Microsoft Azure CDN
      • Twitter CDN
      • Yahoo Image CDN

  • cdns

    1 product used

    • Amazon CloudFront
Learn more on BuiltWith

GSK News and Updates

Jan 12, 2021
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase 1b/2a clinical trial. VIR-7832 is a neutralizing COVID-19 antibody that preclinical data suggests has two distinguishing properties: an enhanced ability to clear infected cells and the potential to enhance virus-specific T-cell function, which could help treat and/or prevent COVID-19 infection.
Dec 21, 2020
Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
TOKYO and CAMBRIDGE, England, Dec. 21, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with GlaxoSmithKline ("GSK")[1]. The single-target agreement is focused on the discovery and...
Dec 17, 2020
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG
Dec 11, 2020
ViiV Healthcare announces positive CHMP opinion for Rukobia (fostemsavir), a first-in-class attachment inhibitor for the treatment of adults with multidrug-resistant HIV with few treatment options available
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of Rukobia (fostemsavir) 600 mg extended-release tablets, a novel attachment inhibitor for the treatment of HIV-1 infection. Fostemsavir, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Dec 11, 2020
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
Dec 08, 2020
FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has accepted a regulatory submission seeking approval for the use of its anti-IL5 biologic Nucala (mepolizumab) as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

GSK Blogs

Jun 12, 2020
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
Press release
Jun 04, 2020
GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
16 presentations, including new analyses from the pivotal DREAMM-2 study and initial results from the DREAMM-4 study
May 28, 2020
GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations
Announcement follows completion of global manufacturing review and decision to invest in expanded manufacturing capacity
May 27, 2020
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma
DREAMM-2 and DREAMM-6 data at ASCO reinforce the potential of GSK’s investigational belantamab mafodotin
May 27, 2020
FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
An approval would give Nucala a third indication in an eosinophil-driven disease
May 21, 2020
GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio
GSK and Samsung Biologics have entered a partnership

You may also be interested in Related companies

logo
Eolo Pharma
EOLO Pharma is a company that focuses on developing drugs targeting the molecular and cellular basis of inflammation-related diseases (e.g. type II diabetes, autoimmune, metabolic syndrome, hypertension, atherosclerosis, etc.)
View company
logo
Schaper & Brummer
HQ
Salzgitter, DE
Employees
27 ↑ 4% increase
Schaper & Brummer is a manufacturer and distributor of pharmaceuticals.
View company
logo
Dalton Pharma Services
HQ
Toronto, CA
Employees
131 ↓ -2% decrease
Dalton Pharma Services is a drug development and manufacturing company.
View company
logo
Kemwell Biopharma
HQ
Bengaluru, IN
Employees
446 ↑ 2% increase
Kemwell Biopharma is a contract biologic development company.
View company
When was GSK founded?
GSK was founded in 2000.
Who are GSK key executives?
GSK's key executives are Faris El Refaie, Iain MacKay and Hal Barron.
How many employees does GSK have?
GSK has 99,437 employees.
What is GSK revenue?
Latest GSK annual revenue is £33.75 b.
What is GSK revenue per employee?
Latest GSK revenue per employee is £339.45 k.
Who are GSK competitors?
Competitors of GSK include Johnson & Johnson, Roche and AstraZeneca.
Where is GSK headquarters?
GSK headquarters is located at 980 Great West Rd, Brentford.
Where are GSK offices?
GSK has offices in Brentford, Philadelphia, Tirane, Boudouaou and 87 other locations
How many offices does GSK have?
GSK has 91 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu

Craft Logo

Products

Solutions

Company

© Craft.co 2021
Share price data provided by IEX